Prognostic and predictive value of ESR1 mutations in postmenopausal metastatic breast cancer (MBC) patients (pts) resistant to aromatase inhibitors (AI), treated with palbociclib (PAL) in combination with endocrine therapy (ET) or capecitabine (CAP) in the PEARL study.

Miguel Martin,Christoph C. Zielinski,Manuel Ruiz Borrego,Eva Carrasco,Eva Ciruelos,Montserrat Muñoz,Begoña Bermejo,Mireia Margeli Vila,Nicholas C. Turner,Maribel Casas,Antonio Antón,Laura Murillo Jaso,István Láng,Cynthia Huang Bartlett,Maria Koehler,Nuria Martin,Massimo Corsaro,Claire Swift,Bella Nisenbaum,Miguel Gil

Prognostic and predictive value of ESR1 mutations in postmenopausal metastatic breast cancer (MBC) patients (pts) resistant to aromatase inhibitors (AI), treated with palbociclib (PAL) in combination with endocrine therapy (ET) or capecitabine (CAP) in the PEARL study.

2020

1022Background: Prior retrospective data has shown ESR1 mutation is an acquired resistant mechanism to AI. However, little is known about ist prognostic and predictive value to endocrine-based ther...

Keywords:

Oncology
Estrogen receptor alpha
Metastatic breast cancer
endocrine therapy
Palbociclib
Aromatase
predictive value
Internal medicine
Pathology
Capecitabine
Medicine
Endocrine system

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations